Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| OptiNose Inc | OPTN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.905 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.905 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.855 - 2.10 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.905 | USD |
OptiNose Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 101.39M | 112.65M | - | 70.99M | -35.48M | -0.32 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
OptiNose News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OPTN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.9327 | 1.25 | 0.855 | 0.9131044 | 5,044,962 | -0.0277 | -2.97% |
| 1 Month | 1.48 | 1.49 | 0.855 | 0.9733506 | 1,646,156 | -0.575 | -38.85% |
| 3 Months | 1.25 | 2.10 | 0.855 | 1.32 | 1,019,041 | -0.345 | -27.60% |
| 6 Months | 1.19 | 2.10 | 0.855 | 1.30 | 637,966 | -0.285 | -23.95% |
| 1 Year | 1.76 | 2.10 | 0.855 | 1.28 | 562,348 | -0.855 | -48.58% |
| 3 Years | 3.735 | 4.30 | 0.855 | 1.88 | 371,767 | -2.83 | -75.77% |
| 5 Years | 9.44 | 11.66 | 0.855 | 3.30 | 364,023 | -8.54 | -90.41% |
OptiNose Description
| OptiNose Inc is a US-based specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. The lead product of the company, XHANCE nasal spray, utilizes a proprietary breath powered exhalation delivery system, to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids. The pipeline products of the company include XHANCE, OPN-300, OPN-021, and AVP-825. |
